Nathanson L, Garrison M
World J Surg. 1995 May-Jun;19(3):337-42. doi: 10.1007/BF00299153.
The progestogen megestrol acetate (160 mg/day PO continuously starting 2 days before chemotherapy) plus chemotherapy with dacarbazine (220 mg/m2/day IV for 3 days), cisplatin (25-30 mg/m2/day IV for 3 days) every 3 weeks, and carmustine (150 mg/m2 IV single dose every 6 weeks) were administered to 22 patients, 18 of whom were evaluable. Toxicity was tolerable, and more than 80% of ideal dosing was achieved during the first two cycles of treatment. A net weight gain of 0.95 kg was observed during this program of treatment. A 56% objective response rate, including visceral responding sites, with a median duration of response of 37.5+ weeks was achieved. A median survival of 15 months for all evaluable study patients was seen, which is somewhat longer than that achieved by most prior studies, including those employing the same chemotherapy regimen plus tamoxifen. Megestrol acetate may contribute to a high objective response rate and prolonged median survival in viscerally dominant metastatic melanoma when used with a chemotherapy regimen of dacarbazine, carmustine, and cisplatin.
对22例患者给予醋酸甲地孕酮（从化疗前2天开始，持续口服，每日160 mg）联合达卡巴嗪（220 mg/m²/日，静脉滴注3天）、顺铂（25 - 30 mg/m²/日，静脉滴注3天），每3周一次，卡莫司汀（150 mg/m²，静脉注射，每6周一次）进行化疗，其中18例可评估疗效。毒性反应可耐受，在前两个治疗周期中达到了超过80%的理想剂量。在该治疗方案期间观察到体重净增加0.95 kg。客观缓解率为56%，包括内脏反应部位，中位缓解持续时间为37.5 +周。所有可评估研究患者的中位生存期为15个月，这比大多数先前研究的结果略长，包括那些采用相同化疗方案加他莫昔芬的研究。当与达卡巴嗪、卡莫司汀和顺铂的化疗方案联合使用时，醋酸甲地孕酮可能有助于内脏型转移性黑色素瘤获得较高的客观缓解率和延长中位生存期。
